Compare The Coca-Cola Co K (KO) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
The Coca-Cola Co K vs BIO-TECHNE Corp — how do they compare? The Coca-Cola Co K trades at $86.82 (market cap $373.76B), while BIO-TECHNE Corp trades at $72.06 (market cap $11.24B). The key difference: The Coca-Cola Co K is far larger — about 33.3× BIO-TECHNE Corp's market cap, and The Coca-Cola Co K pays the higher dividend (2.44%). Which is the better fit depends on your goals.
| KO | TECH | |
|---|---|---|
Market Cap | $373.76B | $11.24B |
Volume | 14,630,257 | — |
Sector | Consumer Staples | Health |
52-Week High | $89.08 | $72.29 |
52-Week Low | $65.67 | $43.31 |
Enterprise Value | $400.93B | $11.32B |
Dividend Yield | 2.44% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coca-Cola (KO) trades at $86.75, down 0.34% on the day, with a bullish technical signal supported by moving averages and oversold RSI levels. The company shows strong profitability with a 28.56% net income margin and consistent earnings beats in recent quarters. Recent news highlights institutional buying and stable demand trends, while dividends continue with a 64-year growth streak.
The stock offers a positive outlook with a consensus price target of $95.83, implying 10% upside, driven by earnings momentum and dividend reliability. Risks include regional demand volatility and high debt levels, but analyst sentiment remains bullish with 60% buy ratings.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
